EMBRACE: The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders.

Sponsor
Peter MacCallum Cancer Centre, Australia (Other)
Overall Status
Recruiting
CT.gov ID
NCT04819607
Collaborator
(none)
100
1
33.7
3

Study Details

Study Description

Brief Summary

This is a prospective hybrid implementation-effectiveness study of a model of care for patients with bone marrow failure syndromes and inherited predisposition to haematological malignancy that includes comprehensive diagnostic genomic evaluation, multidisciplinary case review, provision of clinical care including from clinical haematologists, medical geneticists and genetic counsellors.

Condition or Disease Intervention/Treatment Phase
  • Other: model of care

Detailed Description

The inherited bone marrow disorders (IBMD) comprise both the traditional inherited bone marrow failure syndromes (BMFS) and the more recently described entity of germline predisposition to haematological malignancy. Patients with IBMD often present highly complex health issues that are unique and not commonly encountered. As a consequence, clinicians may feel less confident in managing these unique issues given their lack of frequent exposure to this patient group. Recent advances in genomics have resulted in more accurate diagnosis of IBMD and their subtyping and have resulted in a rapidly evolving field with multiple opportunities to improve patient outcomes.

Stage 1 of this study evaluated and quantified the current challenges faced by 3 stakeholder groups, patients with IBMD, patient advocates and nationally, clinicians who care for IBMD patients. The results demonstrated that the challenges described in Stage 1 may be overcome by instigating a multidisciplinary approach to care for BMF patients. Interventions designed to address the challenges identified in stage 1 form the model of multidisciplinary care to be implemented in the Peter MacCallum Cancer Centre/ Royal Melbourne Hospital clinic. The model of care involves:

  1. Provide access to genetic testing with expert result interpretation

  2. Presentation of clinical information and relevant investigations (including genetic) at a multidisciplinary team meeting involving haematologists, molecular haematopathologists, clinical genetics, genetic counsellors, scientists and specialised nurses.

  3. Provision of a suggested care plan to clinician

  4. Genetic counselling and provision of written disease specific information including details of suggested care plan to patient

  5. Genetic counselling and provision of written information and access to testing for at risk family members

  6. Dedicated team focused on many individually rare diseases with a demonstrated focus on provision of comprehensive care

  7. Opportunity to participate in local and international research

The EMBRACE study will focus on evaluating the model of care.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders.(The EMBRACE Study)
Actual Study Start Date :
Jun 9, 2021
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Apr 1, 2024

Arms and Interventions

Arm Intervention/Treatment
BMFS patients

Patients with BMFS attending Peter MacCallum Cancer Centre haematology clinic.

Other: model of care
Multidisciplinary model of care for BMFS patients.

Outcome Measures

Primary Outcome Measures

  1. to assess the effectiveness and implementation of the model of care through a mixture of objective metrics and patient /physician reported outcomes [12 months]

    Effectiveness - patient/physician reported outcomes of satisfaction with model of care as measured by questionnaire Implementation - compliance with of model as measured by audit against pre-specified key performance indicators

Secondary Outcome Measures

  1. To assess longitudinal quality of life assessment in patients being treated with the model [12 months]

    Longitudinal quality of life assessment in patients being treated with the model measured by the EORTC QLQ-C30

  2. To quantitate healthcare usage of patients within the model [12 months]

    Quantitate healthcare usage of patients within the model measured by questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Patients must meet all the following criteria for study entry:
  1. Age > or = 18 years at enrolment

  2. Able to give informed consent (or responsible family member able to give informed consent)

  3. Patient is receiving care under the institutional guidelines/stream model of care

Exclusion Criteria:
  1. Patient not eligible for management under the model of care

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peter MacCallum Cancer Centre Melbourne Victoria Australia 3000

Sponsors and Collaborators

  • Peter MacCallum Cancer Centre, Australia

Investigators

  • Principal Investigator: Piers Blombery, MBBS(Hons), Peter MacCallum Cancer Centre, Australia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peter MacCallum Cancer Centre, Australia
ClinicalTrials.gov Identifier:
NCT04819607
Other Study ID Numbers:
  • 21/44
First Posted:
Mar 29, 2021
Last Update Posted:
Aug 23, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2021